Core Viewpoint - Nutex Health Inc. is facing a class action lawsuit due to allegations of misleading statements and fraudulent activities related to its financial reporting and arbitration processes [4]. Group 1: Company Performance and Stock Movements - Nutex's share price surged after it began submitting patient bills to arbitration for out-of-network medical bills, but subsequently fell by $11.18, or 10.1%, closing at $100.01 on July 22, 2025, following reports of a fraudulent scheme involving a third-party vendor [2]. - On August 14, 2025, Nutex announced a delay in filing its quarterly financial statements due to non-cash accounting adjustments, leading to a further decline in shares by $18.22, or 16.4%, closing at $92.91 on August 15, 2025 [3]. Group 2: Allegations in the Lawsuit - The class action lawsuit alleges that Nutex made materially false and misleading statements, failing to disclose that its arbitration results were achieved through a coordinated scheme to defraud insurance companies [4]. - It is claimed that revenues from Nutex's engagement with the third-party vendor were unsustainable and that the company overstated its ability to remediate weaknesses in its internal controls over financial reporting [4]. - The lawsuit also states that Nutex improperly classified stock-based compensation obligations, increasing the risk of failing to file financial reports with the SEC in a timely manner [4]. Group 3: Legal Proceedings - Investors who purchased Nutex securities during the class period (August 8, 2024, to August 14, 2025) have until October 21, 2025, to file a lead plaintiff motion in the class action lawsuit [1][5].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making false and misleading statements regarding its business and financial conditions [1][2]. Allegations - Nutex and its executives are accused of failing to disclose material facts about the company's business and finances [2]. - The lawsuit claims that Nutex benefited from arbitration results secured by HaloMD, which is alleged to have engaged in fraudulent schemes to defraud insurance companies [6]. - It is alleged that Nutex reported unsustainable revenues tied to this alleged fraud [6]. - The company is accused of overstating its remediation of internal control weaknesses over financial reporting [6]. - Nutex allegedly failed to properly account for stock-based compensation obligations, misclassifying them as equity instead of liabilities [6]. - The lawsuit highlights an increased risk of delayed SEC filings due to these accounting errors [6]. - Nutex is accused of overstating its business and financial prospects through misleading positive statements [6]. Key Events - On July 22, 2025, a report from Blue Orca Capital alleged that Nutex used HaloMD in fraudulent arbitration schemes, resulting in a stock price drop of $11.18 (10.1%), closing at $100.01 [6]. - On August 14, 2025, Nutex announced a delay in its Q2 2025 financial filings due to accounting issues related to stock-based compensation, leading to a further stock price decline of $18.22 (16.4%), closing at $92.91 on August 15 [6]. Class Period and Deadlines - The class period for the lawsuit is from August 8, 2024, to August 14, 2025 [6]. - The deadline to file a lead plaintiff motion is October 21, 2025 [6].

Core Viewpoint - Nutex is facing significant legal and financial challenges due to allegations of fraudulent activities related to its partnership with HaloMD, which have led to a substantial decline in its stock price [2][3][4]. Group 1: Allegations and Legal Issues - The complaint against Nutex claims that the company and its executives violated federal securities laws by making false statements and failing to disclose critical information regarding their operations with HaloMD [2]. - Allegations include that Nutex engaged in a scheme to defraud insurance companies, resulting in unsustainable revenue from its dealings with HaloMD [2]. - The company is accused of overstating its ability to remediate internal control weaknesses, which affected its financial reporting and stock-based compensation calculations [2]. Group 2: Stock Price Impact - Following the release of a short report by Blue Orca Capital, Nutex's stock price dropped by $11.18 per share, or 10.05%, closing at $100.01 on July 22, 2025 [4]. - After Nutex announced a delay in filing its Form 10-Q due to accounting adjustments, its stock price fell further by $18.22 per share, or 16.39%, closing at $92.91 on August 15, 2025 [4]. Group 3: Company Response - Nutex publicly disagreed with the allegations made in the Blue Orca report and indicated that updates would be provided in its upcoming earnings release [4]. - The company has not effectively rebutted the allegations, which has contributed to the decline in investor confidence and stock value [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business and operations between August 8, 2024, and August 14, 2025 [1][2]. Group 1 - The lawsuit represents a class of investors who purchased or acquired Nutex securities during the specified period [1]. - Defendants are accused of providing misleading information that affected the investors' decisions [2]. - The deadline to file papers to serve as lead plaintiff is October 21, 2025, allowing individuals to represent the class in the litigation [3]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its success in class action litigation [4].

Core Viewpoint - A class-action lawsuit has been filed against Nutex Health, Inc. alleging fraudulent activities that inflated revenues, resulting in significant investor losses [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Nutex and its partner HaloMD engaged in a scheme to defraud insurance companies by submitting ineligible claims, which were falsely attested to as legitimate [2]. - The allegations were initially brought to light by a report from Blue Orca Capital, which accused HaloMD of a coordinated fraudulent scheme to extract millions from insurance companies [3]. - Following the report, Nutex's stock price fell over 10%, indicating a loss of investor confidence [3]. Group 2: Financial Reporting Issues - The lawsuit also alleges that Nutex overstated its progress in addressing weaknesses in its financial reporting controls, leading to improper accounting of stock-based compensation [4]. - Nutex's delay in filing its Form 10-Q due to accounting adjustments further exacerbated the situation, causing a 16.39% drop in its stock price on August 15, 2025 [5]. Group 3: Company Response and Restatement - On August 21, 2025, Nutex filed a Form 8-K stating that certain prior financial statements would need to be restated due to improper treatment of non-cash obligations [6]. - The company did not adequately rebut the allegations made in the Blue Orca report, only noting that it was not named as a defendant in lawsuits against HaloMD [7]. Group 4: Investor Impact and Recovery Efforts - The class action seeks to recover damages for investors who purchased Nutex securities during the specified class period, alleging that public statements were materially false and misleading [8]. - Hagens Berman is investigating the allegations to determine if Nutex's business model was based on fraudulent practices and whether its financial controls misled investors [9].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for failing to disclose fraudulent activities by its third-party arbitration vendor, HaloMD, which has raised concerns about the legitimacy of the company's reported revenues and financial health [1][2][3]. Group 1: Allegations and Concerns - The lawsuit alleges that Nutex Health Inc. did not disclose that HaloMD was involved in a scheme to defraud insurance companies, leading to unsustainable revenue from arbitration results [2]. - It is claimed that Nutex overstated its ability to remediate internal control weaknesses over financial reporting, affecting the accounting of stock-based compensation obligations [2]. - Blue Orca Capital's short report raised alarms about Nutex's 20-fold share price increase, attributing it to inflated billing practices by HaloMD, which could lead to a collapse in financial performance if these practices cease [3]. Group 2: Financial Impact - Following the announcement of a delay in filing quarterly financial statements due to incomplete accounting adjustments, Nutex's stock price dropped over 16% [4]. - The allegations suggest that if the fraudulent revenue streams are cut off, Nutex's stock could revert to penny-stock levels, indicating a significant risk to investors [3]. Group 3: Legal Proceedings - Shareholders are encouraged to participate in the class action lawsuit, with options to serve as lead plaintiff or remain as absent class members [5]. - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees unless a recovery is achieved [6].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 14, 2025and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder ri ...

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for alleged misleading statements and fraudulent activities related to its third-party vendor HaloMD, which reportedly engaged in a scheme to defraud insurance companies [1][5]. Group 1: Events Leading to the Lawsuit - On July 22, 2025, Blue Orca Capital released a report claiming that HaloMD was involved in fraudulent activities, leading to a significant drop in Nutex's share price by approximately 10.05%, from $111.19 to $100.01 per share [3]. - On August 14, 2025, Nutex announced a delay in filing its quarterly report with the SEC due to accounting adjustments, resulting in a further decline in share price by about 16.39%, closing at $92.91 per share on August 15, 2025 [4]. Group 2: Allegations in the Lawsuit - The lawsuit alleges that Nutex made false or misleading statements regarding HaloMD's operations and the sustainability of its revenues [5]. - It is claimed that Nutex overstated its ability to remediate internal control weaknesses and improperly classified stock-based compensation obligations, increasing the risk of delayed financial reporting [5].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. and certain officers for alleged violations of federal securities laws during the class period from August 8, 2024, to August 14, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover damages for all individuals and entities that purchased or acquired Nutex securities within the specified class period [2]. Case Details - The Complaint alleges that Defendants made materially false and misleading statements, including: - HaloMD was involved in a scheme to defraud insurance companies, generating unsustainable revenues for Nutex [3]. - Nutex overstated its remediation of internal control weaknesses and misclassified stock-based compensation obligations [3]. - The Company faced increased risks of failing to file timely financial reports with the SEC, leading to an overstatement of its business and financial prospects [3]. Next Steps - Interested parties can review the Complaint and have until October 21, 2025, to request appointment as lead plaintiff [4]. Legal Representation - The law firm operates on a contingency fee basis, meaning they will only collect fees if successful in recovering funds for investors [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for clients [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nutex Health Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's financial disclosures and practices [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for securities purchased between August 8, 2024, and August 14, 2025, inclusive [1]. - Investors who purchased Nutex securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Allegations Against Nutex Health Inc. - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices, particularly concerning its relationship with HaloMD, a third-party vendor [5]. - Specific claims include that Nutex engaged in a scheme to defraud insurance companies, leading to unsustainable revenue from its arbitration results [5]. - The company is accused of overstating its ability to remediate weaknesses in its internal controls over financial reporting, which affected its accounting for stock-based compensation obligations [5]. - As a result of these alleged misrepresentations, Nutex's business and financial prospects were overstated, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].